# Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Source: https://onco.cc/trials/nct00383708/  
OnCo record `nct00383708` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Somatostatin analogues and Pegvisomant in Pituitary tumours, run by Ipsen, completed.

## Summary

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients is a phase 3 interventional study registered as NCT00383708 by Ipsen, with 125 participants recorded, started 2006-10 and reaching its primary completion in 2008-10. Interventions recorded: lanreotide (Autogel formulation), Pegvisomant. Conditions recorded: Acromegaly.

Linked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00383708
- Phase: 3
- Setting: Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone
- Sponsor: Ipsen
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT00383708: https://clinicaltrials.gov/study/NCT00383708

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Pegvisomant](https://onco.cc/drugs/pegvisomant/), [Somatostatin analogues (octreotide, lanreotide)](https://onco.cc/drugs/octreotide-lanreotide/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)

---
JSON: https://onco.cc/api/v1/entities/nct00383708.json